Early Prediction of Long-Term Response to Cabergoline in Patients with Macroprolactinomas [PDF]
Endocrinology and Metabolism, 2014 BackgroundCabergoline is typically effective for treating prolactinomas; however, some patients display cabergoline resistance, and the early characteristics of these patients remain unclear.
Youngki Lee +5 more
doaj +1 more source
Brusatol Inhibits Tumor Growth and Increases the Efficacy of Cabergoline against Pituitary Adenomas
Oxidative Medicine and Cellular Longevity, 2021 Cabergoline (CAB) is the first choice for treatment of prolactinoma and the most common subtype of pituitary adenoma. However, drug resistance and lack of effectiveness in other pituitary tumor types remain clinical challenges to this treatment. Brusatol
Zerui Wu +7 more
semanticscholar +1 more source
Cabergoline in the Treatment of Male Orgasmic Disorder—A Retrospective Pilot Analysis
Sexual Medicine, 2016 Introduction: Male orgasmic disorder is common, with few treatment options. Cabergoline is a dopamine agonist that acts centrally to normalize serum prolactin that could improve orgasmic dysfunction.
Adam B. Hollander, MD +6 more
doaj +1 more source
A macroprolactinoma becoming resistant to cabergoline and developing atypical pathology [PDF]
, 2016 Pituitary adenomas are a common intracranial neoplasm, usually demonstrating a benign phenotype. They can be classified according to pathological, radiological or clinical behaviour as typical, atypical or carcinomas, invasive or noninvasive, and ...
Ansorge, Olaf +6 more
core +3 more sources
Shrinkage by the third month predicts long-term response of macroprolactinoma after cabergoline.
European Journal of Endocrinology, 2021 OBJECTIVE Transsphenoidal surgery (TSS) is mainly indicated in prolactinomas when dopamine agonist treatment fails. However, there is no established early predictor of cabergoline (CBG) response.
B. Biagetti +8 more
semanticscholar +1 more source
Cabergoline therapy for Macroprolactinoma during pregnancy: A case report
BMC Research Notes, 2012 Background We assessed the safety of Cabergoline therapy during pregnancy in a lady with hyperprolactinemia intolerant to Bromocriptine. Case presentation We report the case of a 31 year old lady who presented to us with uncontrolled hyperprolactinemia ...
Shahzad Hira +2 more
doaj +1 more source
BMC Pharmacology and Toxicology, 2021 Background Dopamine D2 receptor agonists, bromocriptine and cabergoline, are notable medications in the treatment of Parkinsonism, hyperprolactinemia, and hyperglycemia.
Mohammed Ahmed Fouad Shalaby +6 more
doaj +1 more source
Simultaneous pyometra and viable puppies’ gestation in a bitch [PDF]
, 2014 Here we describe a case of pyometra coexisting with gestation in a 4.5 year-old miniature short-haired Dachshund. The dog exhibited depression, vaginal discharge, polydipsia and dehydration. Ultrasound examination revealed the presence of low to moderate
Corrada, Yanina Alejandra +2 more
core +5 more sources
Evaluation of a 5-year programme to prevent mother-to-child transmission of HIV infection in Northern Uganda [PDF]
, 2010 Prevention of mother-to-child transmission (PMTCT) is essential in HIV/AIDS control. We analysed 2000-05 data from mother-infant pairs in our PMTCT programme in rural Uganda, examining programme utilization and outcomes, HIV transmission rates and ...
Ahoua, Laurence +9 more
core +2 more sources
Long-term cardiac (valvulopathy) safety of cabergoline in prolactinoma
Indian Journal of Endocrinology and Metabolism, 2017 Background: Clinical relevance of association of cabergoline use for hyperprolactinemia and cardiac valvulopathy remains unclear. Objective: The aim of the study was to determine the prevalence of valvular heart abnormalities in patients taking ...
Shruti Khare +6 more
doaj +1 more source